p57 Kip2and cancer: Time for a critical appraisal

Molecular Cancer Research

Volumn 9, Issue 10, 2011, Pages 1269-1284

  Borriello, Adriana ^a   Caldarelli, Ilaria ^a   Bencivenga, Debora ^a   Criscuolo, Maria ^a   Cucciolla, Valeria ^a   Tramontano, Annunziata ^a   Oliva, Adriana ^a   Perrotta, Silverio ^a   Ragione, Fulvio Della ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; HISTONE DEACETYLASE; MICRORNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR HES 1;

BECKWITH WIEDEMANN SYNDROME; BREAST CANCER; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL METABOLISM; CELL MIGRATION; CYTOSKELETON; DOWN REGULATION; EMBRYO DEVELOPMENT; ERYTHROPOIESIS; GENE CONTROL; GENE EXPRESSION; GENE STRUCTURE; GENETIC CODE; HUMAN; LARYNX CANCER; LUNG CANCER; MOUTH CANCER; MUTATION; NEOPLASM; NERVE CELL DIFFERENTIATION; NONHUMAN; ORGANOGENESIS; OVARY CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SENESCENCE; STOMACH CANCER; THYROID CANCER; TRANSCRIPTION REGULATION;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P57; HUMANS; MICE; NEOPLASMS;

ANIMALIA;

EID: 80054699958     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0220     Document Type: Review

References (154)

1. Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, et al. Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. Hum Genet 1996;97:625-31.
2. Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, et al. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. Proc Natl Acad Sci U S A 1996;93:3026-30.
3. Lee MP, DeBaun MR, Mitsuya K, Galonek HL, Brandenburg S, Oshimura M, et al. Loss of imprinting of a paternally expressed transcript, with antisense orientation to KVLQT1, occurs frequently in Beckwith-Wiedemann syndrome and is independent of insulin-like growth factor II imprinting. Proc Natl Acad Sci U S A 1999;96:5203-8. (Pubitemid 29214561)
4. Mitsuya K, Meguro M, Lee MP, Katoh M, Schulz TC, Kugoh H, et al. LIT1, an imprinted antisense RNA in the human KvLQT1 locus identified by screening for differentially expressed transcripts using monochromosomal hybrids. Hum Mol Genet 1999;8:1209-17. (Pubitemid 29328989)
5. Smilinich NJ, Day CD, Fitzpatrick GV, Caldwell GM, Lossie AC, Cooper PR, et al. A maternally methylated CpG island in KvLQT1 is associated with an antisense paternal transcript and loss of imprinting in Beckwith-Wiedemann syndrome. Proc Natl Acad Sci U S A 1999;96:8064-9. (Pubitemid 29328408)
6. Engemann S, Strödicke M, Paulsen M, Franck O, Reinhardt R Lane N, et al. Sequence and functional comparison in the Beckwith-Wiedemann region: implications for a novel imprinting centre and extended imprinting. Hum Mol Genet 2000;9:2691-706.
7. Kato R, Shirohzu H, Yokomine T, Mizuno S, Mukai T, Sasaki H. Sequence-ready 1-Mb YAC, BAC and cosmid contigs covering the distal imprinted region of mouse chromosome 7. DNA Res 1999;6:401-5. (Pubitemid 129705041)
8. Mahy NL, Perry PE, Bickmore WA. Gene density and transcription influence the localization of chromatin outside of chromosome territories detectable by FISH. J Cell Biol 2002;159:753-63. (Pubitemid 36008358)
9. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature 2000;405:486-9. (Pubitemid 30367428)
10. Dauphinot L, De Oliveira C, Melot T, Sevenet N, Thomas V, Weissman BE, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2and c-Myc expression. Oncogene 2001;20:3258-65. (Pubitemid 32553678)
11. Figliola R, Busanello A, Vaccarello G, Maione R. Regulation of p57 (KIP2) during muscle differentiation: role of Egr1, Sp1 and DNA hypomethylation. J Mol Biol 2008;380:265-77.
12. Cucciolla V, Borriello A, Criscuolo M, Sinisi AA, Bencivenga D, Tramontano A, et al. Histone deacetylase inhibitors upregulate p57Kip2 level by enhancing its expression through Sp1 transcription factor. Carcinogenesis 2008;29:560-7. (Pubitemid 351404872)
13. Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA, et al. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS ONE 2009;4:e4482.
14. Topark-Ngarm A, Golonzhka O, Peterson VJ, Barrett B Jr, Martinez B, Crofoot K, et al. CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene. J Biol Chem 2006;281:32272-83. (Pubitemid 46036781)
15. Yang X, Karuturi RK, Sun F, Aau M, Yu K, Shao R, et al. CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 2009;4:e5011.
16. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA, Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 2000;275:38524-31. (Pubitemid 32009180)
17. Fu M, Zhu X, Zhang J, Liang J, Lin Y, Zhao L, et al. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 2003;315:33-41. (Pubitemid 37214895)
18. Samuelsson MK, Pazirandeh A, Davani B, Okret S. p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol 1999;13:1811-22. (Pubitemid 30645255)
19. Balint E, Phillips AC, Kozlov S, Stewart CL, Vousden KH. Induction of p57KIP2 expression by p73beta. Proc Natl Acad U S A 2002;99: 3529-34.
20. Beretta C, Chiarelli A, Testoni B, Mantovani R, Guerrini L. Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. Cell Cycle 2005;4:1625-31.
21. Monahan P, Rybak S, Raetzman LT. The notch target gene HES1 regulates cell cycle inhibitor expression in the developing pituitary. Endocrinology 2009;150:4386-94.
22. Arima T, Kamikihara T, Hayashida T, Kato K, Inoue T, Shirayoshi Y, et al. ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome. Nucleic Acids Res 2005;33:2650-60.
23. Medina R, Zaidi SK, Liu CG, Stein JL, van Wijnen AJ, Croce CM, et al. MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 2008;68:2773-80. (Pubitemid 351556275)
24. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008;27:5651-61.
25. Wurz K, Garcia RL, Goff BA, Mitchell PS, Lee JH, Tewari M, et al. MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: relationship to CDKN1B, CDKNIC and overall survival. Genes Chromosomes Cancer 2010;49:577-84.
26. Sun K, Wang W, Zeng JJ, Wu CT, Lei ST, Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin 2011;32:375-84.
27. Fu X, Wang Q, Chen J, Huang X, Chen X, Cao L, et al. Clinical significance of miR-221 and its inverse correlation with p27(Kip1) in hepatocellular carcinoma. Mol Biol Rep 2010;38:3029-35.
28. Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfò L, Rossi C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood 2010;115:3949-59.
29. Kedde M, van Kouwenhove M, Zwart W, Oude Vrielink JA, Elkon R, Agami R. A Pumilio-induced RNA structure switch in p27-3′UTR controls miR-221 and miR-222 accessibility. Nat Cell Biol 2010;12:1014-20.
30. Kim YK, Yu J, Han TS, Park SY, Namkoong B, Kim DH, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 2009;37:1672-81.
31. Sengupta S, Nie J, Wagner RJ, Yang C, Stewart R, Thomson JA. MicroRNA 92b controls the G1/S checkpoint gene p57 in human embryonic stem cells. Stem Cells 2009;27:1524-8.
32. Chen H, Qian K, Tang ZP, Xing B, Chen H, Liu N, et al. Bioinformatics and microarray analysis of microRNA expression profiles of murine embryonic stem cells, neural stem cells induced from ESCs and isolated from E8.5 mouse neural tube. Neurol Res 2010;32:603-13.
33. Hashimoto Y, Kohri K, Kaneko Y, Morisaki H, Kato T, Ikeda K, et al. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression. J Biol Chem 1998;273:16544-50. (Pubitemid 28311440)
34. Joaquin M, Watson RJ. The cell cycle-regulated B-Myb transcription factor overcomes cyclin-dependent kinase inhibitory activity of p57 (KIP2) by interacting with its cyclin-binding domain. J Biol Chem 2003;278:44255-64. (Pubitemid 37377170)
35. Reynaud EG, Pelpel K, Guillier M, Leibovitch MP, Leibovitch SA. p57 (Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts. Mol Cell Biol 1999;19:7621-9. (Pubitemid 29493425)
36. Reynaud EG, Leibovitch MP, Tintignac LA, Pelpel K, Guillier M, Leibovitch SA. Stabilization of MyoD by direct binding to p57 (Kip2). J Biol Chem 2000;275:18767-76. (Pubitemid 30422837)
37. Kitzmann M, Fernandez A. Crosstalk between cell cycle regulators and the myogenic factor MyoD in skeletal myoblasts. Cell Mol Life Sci 2001;58:571-9. (Pubitemid 32382258)
38. Vaccarello G, Figliola R, Cramerotti S, Novelli F, Maione R. p57Kip2 is induced by MyoD through a p73-dependent pathway. J Mol Biol 2006;356:578-88. (Pubitemid 43139321)
39. Joseph B, Andersson ER, Vlachos P, Södersten E, Liu L, Teixeira AI, et al. p57Kip2 is a repressor of Mash1 activity and neuronal differentiation in neural stem cells. Cell Death Differ 2009;16:1256-65.
40. Joseph B, Wallén-Mackenzie A, Benoit G, Murata T, Joodmardi E, Okret S, et al. p57(Kip2) cooperates with Nurr1 in developing dopamine cells. Proc Natl Acad Sci U S A 2003;100:15619-24. (Pubitemid 38021039)
41. Yokoo T, Toyoshima H, Miura M, Wang Y, Iida KT, Suzuki H, et al. p57Kip2 regulates actin dynamics by binding and translocating LIM-kinase 1 to the nucleus. J Biol Chem 2003;278:52919-23. (Pubitemid 38035893)
42. Heinen A, Kremer D, Hartung HP, Küry P. p57 kip2's role beyond Schwann cell cycle control. Cell Cycle 2008;7:2781-6.
43. Kremer D, Heinen A, Jadasz J, Göttle P, Zimmermann K, Zickler P, et al. p57kip2 is dynamically regulated in experimental autoimmune encephalomyelitis and interferes with oligodendroglial maturation. Proc Natl Acad Sci U S A 2009;106:9087-92.
44. Vlachos P, Joseph B. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics. Oncogene 2009;28:4175-88.
45. Tury A, Mairet-Coello G, Dicicco-Bloom E. The cyclin-dependent kinase inhibitor p57Kip2 regulates cell cycle exit, differentiation, and migration of embryonic cerebral cortical precursors. Cereb Cortex 2011;21:1840-56.
46. Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A 1998;95:1392-7.
47. Chang TS, Kim MJ, Ryoo K, Park J, Eom SJ, Shim J, et al. p57KIP2 modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein kinase. J Biol Chem 2003;278:48092-8. (Pubitemid 37523260)
48. Yamamoto T, Digumarthi H, Aranbayeva Z, Wataha J, Lewis J, Messer R, et al. EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells: role of c-Jun N-terminal kinase. Toxicol Appl Pharmacol 2007;224:318-25. (Pubitemid 47592858)
49. Lee MH, Reynisdóttir I, Massagué J. Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995;9:639-49.
50. Adkins JN, Lumb KJ. Intrinsic structural disorder and sequence features of the cell cycle inhibitor p57Kip2. Proteins 2002;46:1-7. (Pubitemid 34033571)
51. Galea CA, Nourse A, Wang Y, Sivakolundu SG, Heller WT, Kriwacki RW. Role of intrinsic flexibility in signal transduction mediated by the cell cycle regulator, p27 Kip1. J Mol Biol 2008;376:827-38.
52. Lacy ER, Filippov I, Lewis WS, Otieno S, Xiao L, Weiss S, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding-induced protein folding. Nat Struct Mol Biol 2004;11:358-64. (Pubitemid 38436801)
53. Lacy ER, Wang Y, Post J, Nourse A, Webb W, Mapelli M, et al. Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division. J Mol Biol 2005;349:764-73. (Pubitemid 40725953)
54. Kip1exhibits intrinsic structure resembling the Cdk2/cyclin A-bound conformation. J Mol Biol 2005;353:1118-28.
55. Galea CA, Wang Y, Sivakolundu SG, Kriwacki RW. Regulation of cell division by intrinsically unstructured proteins: intrinsic flexibility, modularity, and signaling conduits. Biochemistry 2008;47:7598-609. (Pubitemid 352019491)
56. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57Kip2 mediated by SCFSkp2-dependent ubiquitylation. Proc Natl Acad Sci U S A 2003;100:10231-6. (Pubitemid 37071861)
57. Dephoure N, Zhou C, Villén J, Beausoleil SA, Bakalarski CE, Elledge SJ, et al. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 2008;105:10762-7.
58. Xing J, Zhang Z, Mao H, Schnellmann RG, Zhuang S. Src regulates cell cycle protein expression and renal epithelial cell proliferation via PI3K/Akt signaling-dependent and -independent mechanisms. Am J Physiol Renal Physiol 2008;295:F145-52.
59. Borriello A, Caldarelli I, Bencivenga D, Cucciolla V, Oliva A, Usala E, et al. p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells. Carcinogenesis 2011;32:10-8.
60. Leibovitch MP, Kannengiesser C, Leibovitch SA. Signal-induced ubiquitination of p57(Kip2) is independent of the C-terminal consensus Cdk phosphorylation site. FEBS Lett 2003;543:125-8. (Pubitemid 36577240)
61. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep 2008;9:878-84.
62. Reynaud EG, Guillier M, Leibovitch MP, Leibovitch SA. Dimerization of the amino terminal domain of p57Kip2 inhibits cyclin D1-cdk4 kinase activity. Oncogene 2000;19:1147-52. (Pubitemid 30157544)
63. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994;8:9-22.
64. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74. (Pubitemid 24228301)
65. Hattori N, Davies TC, Anson-Cartwright L, Cross JC. Periodic expression of the cyclin-dependent kinase inhibitor p57(Kip2) in trophoblast giant cells defines a G2-like gap phase of the endocycle. Mol Biol Cell 2000;11:1037-45. (Pubitemid 30159320)
66. Yan Y, Frisén J, Lee MH, Massagué J, Barbacid M. Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 1997;11:973-83. (Pubitemid 27199877)
67. Zhang P, Liégeois NJ, Wong C, Finegold M, Hou H, Thompson JC, et al. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-8. (Pubitemid 27209424)
68. Takahashi K, Nakayama K, Nakayama K. Mice lacking a CDK inhibitor, p57Kip2, exhibit skeletal abnormalities and growth retardation. J Biochem 2000;127:73-83. (Pubitemid 30094096)
69. Gao CY, Rampalli AM, Cai HC, He HY, Zelenka PS. Changes in cyclin dependent kinase expression and activity accompanying lens fiber cell differentiation. Exp Eye Res 1999;69:695-703. (Pubitemid 30046895)
70. Gómez Lahoz E, Liegeois NJ, Zhang P, Engelman JA, Horner J, Silverman A, et al. Cyclin D- and E-dependent kinases and the p57 (KIP2) inhibitor: cooperative interactions in vivo. Mol Cell Biol 1999;19:353-63. (Pubitemid 29018437)
71. Cunningham JJ, Roussel MF. Cyclin-dependent kinase inhibitors in the development of the central nervous system. Cell Growth Differ 2001;12:387-96. (Pubitemid 32762688)
72. Itoh Y, Masuyama N, Nakayama K, Nakayama KI, Gotoh Y. The cyclin-dependent kinase inhibitors p57 and p27 regulate neuronal migration in the developing mouse neocortex. J Biol Chem 2007;282:390-6. (Pubitemid 47076663)
73. Ye W, Mairet-Coello G, Pasoreck E, Dicicco-Bloom E. Patterns of p57Kip2 expression in embryonic rat brain suggest roles in progenitor cell cycle exit and neuronal differentiation. Dev Neurobiol 2009;69:1-21.
74. Dugas JC, Ibrahim A, Barres BA. A crucial role for p57(Kip2) in the intracellular timer that controls oligodendrocyte differentiation. J Neurosci 2007;27:6185-96. (Pubitemid 46890015)
75. Rivera FJ, Steffenhagen C, Kremer D, Kandasamy M, Sandner B, Couillard-Despres S, et al. Deciphering the oligodendrogenic program of neural progenitors: cell intrinsic and extrinsic regulators. Stem Cells Dev 2010;19:595-606.
76. Dyer MA, Cepko CL. p57(Kip2) regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina. Development 2000;127:3593-605.
77. Heinen A, Kremer D, Göttle P, Kruse F, Hasse B, Lehmann H, et al. The cyclin-dependent kinase inhibitor p57kip2 is a negative regulator of Schwann cell differentiation and in vitro myelination. Proc Natl Acad Sci U S A 2008;105:8748-53. (Pubitemid 351987751)
78. Zhang P, Wong C, Liu D, Finegold M, Harper JW, Elledge SJ. p21 (CIP1) and p57(KIP2) control muscle differentiation at the myogenin step. Genes Dev 1999;13:213-24. (Pubitemid 29061951)
79. Hiromura K, Haseley LA, Zhang P, Monkawa T, Durvasula R, Petermann AT, et al. Podocyte expression of the CDK-inhibitor p57 during development and disease. Kidney Int 2001;60:2235-46. (Pubitemid 33070466)
80. Ullah Z, Kohn MJ, Yagi R, Vassilev LT, DePamphilis ML. Differentiation of trophoblast stem cells into giant cells is triggered by p57/Kip2 inhibition of CDK1 activity. Genes Dev 2008;22:3024-36.
81. Ullah Z, Lee CY, Depamphilis ML. Cip/Kip cyclin-dependent protein kinase inhibitors and the road to polyploidy. Cell Div 2009;4:10.
82. Gosselet FP, Magnaldo T, Culerrier RM, Sarasin A, Ehrhart JC. BMP2 and BMP6 control p57(Kip2) expression and cell growth arrest/terminal differentiation in normal primary human epidermal keratinocytes. Cell Signal 2007;19:731-9. (Pubitemid 46275366)
83. Georgia S, Soliz R, Li M, Zhang P, Bhushan A. p57 and Hes1 coordinate cell cycle exit with self-renewal of pancreatic progenitors. Dev Biol 2006;298:22-31. (Pubitemid 44414792)
84. Jeong JS, Lee JH, Kim HI, Park JI. Changes in expression of cell cycle regulators and their hepatic lobular distribution in partial hepatectomy-induced regenerating rat liver. J Korean Med Sci 1999;14:635-42.
85. Awad MM, Sanders JA, Gruppuso PA. A potential role for p15(Ink4b) and p57(Kip2) in liver development. FEBS Lett 2000;483:160-4.
86. Li G, Domenico J, Lucas JJ, Gelfand EW. Identification of multiple cell cycle regulatory functions of p57Kip2 in human T lymphocytes. J Immunol 2004;173:2383-91. (Pubitemid 39063094)
87. Kim ST, Gye MC. Expression of p57 in mouse and human testes. Dev Growth Differ 2004;46:495-502. (Pubitemid 40052755)
88. Kim ST, Park NC, Yi LS, Gye MC. Expression of p57kip2 in germ cells and Leydig cells in human testis. Arch Androl 2006;52:463-9. (Pubitemid 44527209)
89. Stewart MC, Kadlcek RM, Robbins PD, MacLeod JN, Ballock RT. Expression and activity of the CDK inhibitor p57Kip2 in chondrocytes undergoing hypertrophic differentiation. J Bone Miner Res 2004;19:123-32. (Pubitemid 41295145)
90. Solomon LA, Li JR, Bérubé NG, Beier F. Loss of ATRX in chondrocytes has minimal effects on skeletal development. PLoS ONE 2009;4:e7106.
91. Hirata M, Kugimiya F, Fukai A, Ohba S, Kawamura N, Ogasawara T, et al. C/EBPbeta promotes transition from proliferation to hypertrophic differentiation of chondrocytes through transactivation of p57. PLoS ONE 2009;4:e4543.
92. Kobayashi H, Kambe F, Imai T, Hibi Y, Kikumori T, Ohmori S, et al. Differential expression of cyclin-dependent kinase inhibitors, p27Kip1 and p57Kip2, by corticotropin in rat adrenal cortex. J Endocrinol 2006;189:671-9.
93. Susaki E, Nakayama K, Yamasaki L, Nakayama KI. Common and specific roles of the related CDK inhibitors p27 and p57 revealed by a knock-in mouse model. Proc Natl Acad Sci U S A 2009;106:5192-7.
94. Scandura JM, Boccuni P, Massagué J, Nimer SD. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci U S A 2004;101:15231-6. (Pubitemid 39391747)
95. Umemoto T, Yamato M, Nishida K, Yang J, Tano Y, Okano T. p57Kip2 is expressed in quiescent mouse bone marrow side population cells. Biochem Biophys Res Commun 2005;337:14-21. (Pubitemid 41393752)
96. Rodriguez S, Wang L, Mumaw C, Srour EF, Lo Celso C, Nakayama K, et al. The SKP2 E3 ligase regulates basal homeostasis and stress-induced regeneration of HSCs. Blood 2011;117:6509-19.
97. Zhang Y, Stehling-Sun S, Lezon-Geyda K, Juneja SC, Coillard L, Chatterjee G, et al. PR domain-containing Mds1-Evi1 is critical for long-term hematopoietic stem cells function. Blood 2011 Jun 10 [Epub ahead of print].
98. Pop R, Shearstone JR, Shen Q, Liu Y, Hallstrom K, Koulnis M, et al. A key commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition between PU.1 and S-phase progression. PLoS Biol 2010;8:e1000484.
99. Samuelsson MK, Pazirandeh A, Okret S. A pro-apoptotic effect of the CDK inhibitor p57(Kip2) on staurosporine-induced apoptosis in HeLa cells. Biochem Biophys Res Commun 2002;296:702-9.
100. Vlachos P, Nyman U, Hajji N, Joseph B. The cell cycle inhibitor p57 (Kip2) promotes cell death via the mitochondrial apoptotic pathway. Cell Death Differ 2007;14:1497-507. (Pubitemid 47086736)
101. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res 2005;65:2186-92. (Pubitemid 40490126)
102. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P, Liloglou T, et al. Downregulation of the KIP family members p27 (KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57 (KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006;119:2546-56. (Pubitemid 44691307)
103. Tsugu A, Sakai K, Dirks PB, Jung S, Weksberg R, Fei YL, et al. Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. Am J Pathol 2000;157:919-32. (Pubitemid 32109384)
104. Schwarze SR, Shi Y, Fu VX, Watson PA, Jarrard DF. Role of cyclin-dependent kinase inhibitors in the growth arrest at senescence in human prostate epithelial and uroepithelial cells. Oncogene 2001;20:8184-92. (Pubitemid 34038207)
105. Ma Y, Chen L, Wright GM, Pillai SR, Chellappan SP, Cress WD. CDKN1C negatively regulates RNA polymerase II C-terminal domain phosphorylation in an E2F1-dependent manner. J Biol Chem 2010;285:9813-22.
106. Takahashi K, Kobayashi T, Kanayama N. p57(Kip2) regulates the proper development of labyrinthine and spongiotrophoblasts. Mol Hum Reprod 2000;6:1019-25.
107. Bonilla F, Orlow I, Cordón-Cardó C. Mutational study of p16CDKN2/MTS1/INK4A and p57KIP2 genes in hepatocellular carcinoma. Int J Oncol 1998;12:583-8.
108. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L, et al. Gain of imprinting at chromosome 11p15: a pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci U S A 2000;97:5445-9. (Pubitemid 30313738)
109. Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 2000;157:1393-403.
110. Guo H, Nan K, Hu T, Meng J, Hui W, Zhang X, et al. Prognostic significance of co-expression of nm23 and p57 protein in hepatocellular carcinoma. Hepatol Res 2010;40:1107-16.
111. Oya M, Schulz WA. Decreased expression of p57(KIP2)mRNA in human bladder cancer. Br J Cancer 2000;83:626-31. (Pubitemid 30636304)
112. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 2005;114:406-13. (Pubitemid 40279961)
113. Bozdoǧan O, Atasoy P, Batislam E, Başar MM, Başar H. Significance of p57(Kip2) down-regulation in oncogenesis of bladder carcinoma: an immunohistochemical study. Tumori 2008;94:556-62.
114. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Matsuura N. Expression of p57/Kip2 protein in pancreatic adenocarcinoma. Pancreas 2001;23:246-50. (Pubitemid 32910972)
115. Sato N, Matsubayashi H, Abe T, Fukushima N, Goggins M. Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling. Clin Cancer Res 2005;11:4681-8. (Pubitemid 41557185)
116. Noura S, Yamamoto H, Sekimoto M, Takemasa I, Miyake Y, Ikenaga M, et al. Expression of second class of KIP protein p57KIP2 in human colorectal carcinoma. Int J Oncol 2001;19:39-47.
117. Li JQ, Wu F, Usuki H, Kubo A, Masaki T, Fujita J, et al. Loss of p57KIP2 is associated with colorectal carcinogenesis. Int J Oncol 2003;23:1537-43.
118. Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palù G, et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 2001;145:207-12. (Pubitemid 32707608)
119. Bourcigaux N, Gaston V, Logié A, Bertagna X, Le Bouc Y, Gicquel C. High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors. J Clin Endocrinol Metab 2000;85:322-30. (Pubitemid 32268833)
120. Ito Y, Yoshida H, Nakano K, Kobayashi K, Yokozawa T, Hirai K, et al. Expression of p57/Kip2 protein in normal and neoplastic thyroid tissues. Int J Mol Med 2002;9:373-6.
121. Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H, et al. Expression of the components of the Cip/Kip family in malignant lymphoma of the thyroid. Pathobiology 2004;71:164-70. (Pubitemid 38437712)
122. Melck A, Masoudi H, Griffith OL, Rajput A, Wilkins G, Bugis S, et al. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol 2007;14:3403-11. (Pubitemid 350160133)
123. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tokuda M. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors. Anticancer Res 2002;22[6A]:3191-6. (Pubitemid 36070092)
124. Khouja MH, Baekelandt M, Nesland JM, Holm R. The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 2007;26:418-25. (Pubitemid 47476327)
125. Shin JY, Kim HS, Lee KS, Kim J, Park JB, Won MH, et al. Mutation and expression of the p27KIP1 and p57KIP2 genes in human gastric cancer. Exp Mol Med 2000;32:79-83. (Pubitemid 30450085)
126. Liang B, Wang S, Yang X, Ye Y, Yu Y, Cui Z. Expressions of cyclin E, cyclin dependent kinase 2 and p57(KIP2) in human gastric cancer. Chin Med J (Engl) 2003;116:20-3. (Pubitemid 36432715)
127. Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 2002;21:2741-9. (Pubitemid 34478332)
128. Fan GK, Chen J, Ping F, Geng Y. Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral Oncol 2006;42:147-53. (Pubitemid 43106879)
129. Fan GK, Xu F, Yang B, Fujieda S. p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. Acta Otolaryngol 2006;126:301-5. (Pubitemid 43259236)
130. Yang CJ, Shen WG, Liu CJ, Chen YW, Lu HH, Tsai MM, et al. MiR-221 and miR-222 expression increased the growth and tumorigenesis of oral carcinoma cells. J Oral Pathol Med 2011;40:560-6.
131. Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, et al. Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther 2003;2:291-8.
132. Kobatake TYano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004;12:1087-92.
133. Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, et al. CDKN1C/p57kip2 is a candidate tumor suppressor gene in human breast cancer. BMC Cancer 2008;8:68-77.
134. Iolascon A, Della Ragione F, Giordani L, Serra A, Saglio G, Faienza MF. Expression of cell cycle regulatory genes in chronic myelogenous leukemia. Haematologica 1998;83:771-7. (Pubitemid 28496164)
135. Li Y, Nagai H, Ohno T, Yuge M, Hatano S, Ito E, et al. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002;100:2572-7.
136. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, et al. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003;101:4131-6. (Pubitemid 36857895)
137. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Prosper F, Heiniger A, Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 2005;23:7043-9.
138. Gutiérrez MI, Siraj AK, Ibrahim MM, Hussain A, Bhatia K. Childhood and adult ALL: differences in epigenetic lesions associated with cell cycle genes. Am J Hematol 2005;80:158-60. (Pubitemid 41434202)
139. Canalli AA, Yang H, Jeha S, Hoshino K, Sanchez-Gonzalez B, Brandt M, et al. Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia. Leuk Res 2005;29:881-5. (Pubitemid 40840715)
140. Bueso-Ramos C, Xu Y, McDonnell TJ, Brisbay S, Pierce S, Kantarjian H, et al. Protein expression of a triad of frequently methylated genes, p73, p57Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol 2005;23:3932-9. (Pubitemid 46218696)
141. Brakensiek K, Länger F, Kreipe H, Lehmann U. Absence of p21(CIP 1), p27(KIP 1) and p 57(KIP 2) methylation in MDS and AML. Leuk Res 2005;29:1357-60. (Pubitemid 41297650)
142. Chim CS, Wong AS, Kwong YL. Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias. Am J Hematol 2005;80:282-7. (Pubitemid 41746175)
143. Chim CS, Fung TK, Wong KF, Lau JS, Law M, Liang R. Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J Clin Pathol 2006;59:921-6. (Pubitemid 44422844)
144. Lee SM, Lee EJ, Ko YH, Lee SH, Maeng L, Kim KM. Prognostic significance of O6-methylguanine DNA methyltransferase and p57 methylation in patients with diffuse large B-cell lymphomas. APMIS 2009;117:87-94.
145. Hagiwara K, Li Y, Kinoshita T, Kunishma S, Ohashi H, Hotta T, et al. Aberrant DNA methylation of the p57KIP2 gene is a sensitive biomarker for detecting minimal residual disease in diffuse large B cell lymphoma. Leuk Res 2010;34:50-4.
146. Stebbing J, Bower M, Syed N, Smith P, Yu V, Crook T. Epigenetics: an emerging technology in the diagnosis and treatment of cancer. Pharmacogenomics 2006;7:747-57. (Pubitemid 44219404)
147. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-20- deoxycytidine with valproic acid in patients with leukemia. Blood 2006;108:3271-9.
148. Qiu X, Hother C, Ralfkiær UM, Sógaard A, Lu Q, Workman CT, et al. Equitoxic doses of 5-azacytidine and 5-aza-2′deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome. PLoS ONE 2010;5:e12994.
149. Shin J-Y, Kim H-S, Park J, Park J-B, Lee J-Y. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 2000;60:262-5. (Pubitemid 30070747)
150. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001;1:194-202. (Pubitemid 33741894)
151. Walkinshaw DR, Yang XJ. Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 2008;15:237-43.
152. Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-9. (Pubitemid 43927132)
153. Lu L, Qiu J, Liu S, Luo W. Vitamin D3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol Cancer Ther 2008;7:1268-74.
154. Kuroda J, Kimura S, Segawa H, Sato K, Matsumoto S, Nogawa M, et al. p53-independent anti-tumor effects of the nitrogencontaining bisphosphonate zoledronic acid. Cancer Sci 2004;95:186-92. (Pubitemid 38404322)